http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Manabu Seino (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment
Manabu Seino,Satoru Nagase,Hideki Tokunaga,Wataru Yamagami,Yoichi Kobayashi,Tsutomu Tabata,Masanori Kaneuchi 대한부인종양학회 2024 Journal of Gynecologic Oncology Vol.35 No.1
The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2022 for the Treatment ofUterine Cer vical Cancer are revised from the 2017 guideline. This guideline aimed to providestandard care for cer vical cancer, indicate appropriate current treatment methods for cer vicalcancer, minimize variances in treatment methods among institutions, improve diseaseprognosis and treatment safety, reduce the economic and psychosomatic burden of patientsby promoting the performance of appropriate treatment, and enhance mutual understandingbetween patients and healthcare professionals. The guidelines were prepared through theconsensus of the JSGO Guideline Committee, based on a careful review of evidence gatheredthrough the literature searches and the medical health insurance system and actual clinicalpractice situations in Japan. The guidelines comprise seven chapters and 5 algorithms. The main features of the 2022 revision are as follows: 1) added discussed points at the finalconsensus meeting; 2) revised the treatment methods based on the International Federationof Gynecology and Obstetrics 2018 staging system; 3) examined minimally invasive surger ybased on Laparoscopic Approach to Cer vical Cancer trial; 4) added clinical question (CQ)for treatments of rare histological types, gastric type, and small-cell neuroendocrinecarcinoma; 5) added CQ for intensity-modulated radiation therapy; 6) added CQ for cancergenomic profiling test; and 7) added CQ for cancer sur vivorship. Each recommendationis accompanied by a classification of recommendation categories based on the consensusreached by the Guideline Committee members. Here, we present the English version of theJSGO Guidelines 2022 for the Treatment of Uterine Cer vical Cancer.
-
Manabu Seino,Satoru Nagase,Tsuyoshi Ohta,Wataru Yamagami,Yasuhiko Ebina,Yoichi Kobayashi,Tsutomu Tabata,Masanori Kaneuchi,Takayuki Enomoto,Mikio Mikami 대한부인종양학회 2023 Journal of Gynecologic Oncology Vol.34 No.1
Objective: The aim of this study was to review the clinicopathological characteristics of small cell neuroendocrine cervical cancer (SCNEC) and to identify the optimal treatment. Methods: The Japanese Society of Gynecologic Oncology conducted a retrospective cohort study of SCNECs enrolled in the Gynecological Tumor Registry of the Japan Society of Obstetrics and Gynecology between 2004 and 2015. All cases were modified and unified by International Federation of Gynecology and Obstetrics 2008 (Union for International Cancer Control 7th edition). Results: There were 822 registered patients diagnosed with SCNEC from 2004 to 2015 which comprised 1.1% (822/73,698) of all uterine cervical cancer cases. Rates of lymph-node and distant metastasis were significantly higher in T1b2 (38.9% and 13.7%, respectively) than T1b1 (14.2% and 4.4%, respectively) (p<0.01). In IB2 and T1bN1M0 SCNEC, the 5-year survival rate with surgery followed by chemotherapy was significantly higher than that with surgery followed by radiation therapy/concurrent chemoradiation therapy (p<0.01). Conclusion: SNCEC tumors >4 cm in size had greater rates of lymph-node and distant metastasis when compared with tumors ≤4 cm. Adjuvant chemotherapy, rather than radiotherapy, may improve prognosis after surgery in T1bN1M0 SCNEC.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
